Financial Results for the quarter ended 31st December 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Kabra Drugs Ltd reported strong results for Q3 FY26, with revenue from operations at ₹3,042 lakhs, up sharply from ₹715 lakhs in Q3 FY25 (a jump of over 4x year-on-year). Net profit for the quarter stood at ₹256.65 lakhs (EPS ₹1.08), compared to a loss of ₹49.98 lakhs (EPS negative ₹0.21) in the same quarter last year. For the nine months ended December 2025, the company posted a revenue of ₹5,733.40 lakhs and a net profit of ₹390.34 lakhs, turning around from a loss of ₹147.85 lakhs in the corresponding nine-month period of the previous year. The statutory auditors issued an unqualified limited review report with no qualifications or matters of concern. The company also noted that paid-up share capital increased during the year (from ₹1,007.91 lakhs to ₹2,370.79 lakhs), indicating a possible stock split or bonus issue.
The company has moved firmly into profitability with a sharp jump in revenue and bottom-line, which is positive for shareholders. Clean audit review and no flagged risks support a constructive short-term view, though investors should track sustainability of this revenue surge.